Survival Study in Patients Undergoing On-line Hemodiafiltration

Patients on hemodialysis will be randomly assigned (1:1) to continue on conventional hemodialysis or on-line hemodiafiltration, both three times per week. A 3 year follow-up and a sample size of around 750 will be necessary to detect a 35% reduction in mortality.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hemodialysis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hospital Clinic de Barcelona, Barcelona, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 18 and older
Currently undergoing hemodialysis
Clinical stability
Stable vascular access

Exclusion criteria

Chronic inflammatory diseases
Liver cirrhosis
Malignancies
Chronic immunosuppressant or antiinflammatory use
Dialysis through temporary catheter or single puncture

Treatment and study plan

hemodialysis

Procedure

3 times per week

on-line hemodiafiltration

Procedure

3 times per week

Primary outcomes

Survival

Time frame: 36 months

Sponsors and collaborators

Lead sponsor

Hospital Clinic of Barcelona

Other

Collaborators

Societat Catalana de Nefrologia

Registry information

Official study title

A Randomized Study to Evaluate Survival in Patients Undergoing Hemodialysis or On-line Hemodiafiltration

Acronym: ESHOL

Important dates

Study start: 2007
Primary completion: 2012
Study completion: 2012
First posted: Jun 10, 2008
Registry last updated: Feb 28, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed